Literature DB >> 15937202

Direct thrombin inhibitors: novel antithrombotics on the horizon in the thromboprophylactic management of atrial fibrillation.

R Katira1, A Chauhan, R S More.   

Abstract

Antithrombotic agents have verified efficacy in reducing the thromboembolic risk associated with atrial fibrillation. This article focuses on the emergence of a new oral direct thrombin inhibitor, ximelagatran, into the arena of atrial fibrillation thromboprophylaxis. This review does not cover atrial fibrillation in the context of valvular heart disease. The efficacy of aspirin and warfarin will be discussed briefly.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15937202      PMCID： PMC1743289          DOI： 10.1136/pgmj.2004.024521

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN： 0032-5473            Impact factor:   2.401


  53 in total

Review 1.  Antithrombotic therapy in atrial fibrillation.

Authors:  G W Albers; J E Dalen; A Laupacis; W J Manning; P Petersen; D E Singer
Journal:  Chest       Date:  2001-01       Impact factor: 9.410

Review 2.  Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range.

Authors:  J Hirsh; J Dalen; D R Anderson; L Poller; H Bussey; J Ansell; D Deykin
Journal:  Chest       Date:  2001-01       Impact factor: 9.410

Review 3.  Use of oral anticoagulants in older patients.

Authors:  J L Sebastian; D D Tresch
Journal:  Drugs Aging       Date:  2000-06       Impact factor: 3.923

Review 4.  Why do patients with atrial fibrillation not receive warfarin?

Authors:  T J Bungard; W A Ghali; K K Teo; F A McAlister; R T Tsuyuki
Journal:  Arch Intern Med       Date:  2000-01-10

5.  Adequacy of anticoagulation in patients with atrial fibrillation coming to a hospital.

Authors:  T J Bungard; M L Ackman; G Ho; R T Tsuyuki
Journal:  Pharmacotherapy       Date:  2000-09       Impact factor: 4.705

6.  Effects of agents, used to treat bleeding disorders, on bleeding time prolonged by a very high dose of a direct thrombin inhibitor in anesthesized rats and rabbits.

Authors:  M Elg; S Carlsson; D Gustafsson
Journal:  Thromb Res       Date:  2001-02-01       Impact factor: 3.944

7.  Underutilization of oral anticoagulant therapy for stroke prevention in elderly patients with heart failure.

Authors:  S A Ibrahim; C K Kwoh
Journal:  Am Heart J       Date:  2000-08       Impact factor: 4.749

8.  Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study.

Authors:  A S Go; E M Hylek; K A Phillips; Y Chang; L E Henault; J V Selby; D E Singer
Journal:  JAMA       Date:  2001-05-09       Impact factor: 56.272

9.  Anticoagulant-related bleeding in older persons with atrial fibrillation: physicians' fears often unfounded.

Authors:  Malcolm Man-Son-Hing; Andreas Laupacis
Journal:  Arch Intern Med       Date:  2003-07-14

10.  Pharmacokinetics and pharmacodynamics of ximelagatran, a novel oral direct thrombin inhibitor, in young healthy male subjects.

Authors:  Ulf G Eriksson; Ulf Bredberg; Kristina Gislén; Linda C Johansson; Lars Frison; Martin Ahnoff; David Gustafsson
Journal:  Eur J Clin Pharmacol       Date:  2003-03-27       Impact factor: 2.953
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.